Loading stock data…
$26.85-2.10 (-7.25%)
Parabilis Medicines, Inc.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | $148,000 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — |
| Operating Income | -$50.89M↓ | -$47.45M↓ | -$36.52M↑ | -$40.24M |
| Net Income | -$52.46M↓ | -$45.32M↓ | -$34.81M↑ | -$38.33M |
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery plat...